Valuation dashboard for Lunai Bioworks Inc. (LNAI) with P/E N/A, P/B -0.71, EV/EBITDA -0.07 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
Valuation Ratios
| Price / Book | -0.71 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LNAI | Lunai Bioworks Inc. | $10M | 8.9% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $2.17 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 892.52% |
| Return on Invested Capital | 120.87% |
| Return on Assets | -1300.98% |
| Gross Margin | -360.71% |
| Operating Margin | -46991.97% |
| Net Margin | -612568.11% |
Explore sector: Healthcare · Biotechnology
More sections of LNAI: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks